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ABSTRACT 
 
Background: The human immunodeficiency virus (HIV) infection can lead to the 
development of HIVAN with the majority of patients progressing to end-stage kidney 
disease. Importantly, individuals of African ancestry are more at risk of developing HIVAN 
than their European descent counterparts. Early diagnosis and immediate nephrology referral 
are key steps in management because this enable predialysis education, allows for 
implementation of preventive measures that delay or even halt progression of HIVAN to end-
stage kidney disease, as well as decrease morbidity and mortality. Currently, the diagnosis of 
HIVAN requires a kidney biopsy. Due to the development of genomics, epigenetics, 
transcriptomics, proteomics, and metabolomics, the introduction of novel techniques will 
allow for the identification of novel biomarkers in kidney diseases. Previous studies have 
recognized basic fibroblast growth factor (bFGF) as a biomarker for HIVAN, since 
significant levels of bFGF low affinity receptors have been previously found in the kidneys 
from HIV infected children. bFGF is an angiogenic growth factor that is involved in kidney 
growth and the pathogenesis of kidney diseases.  
The aim of this study was to investigate the use of  basic fibroblast growth factor (bFGF) as a 
non-invasive biomarker for the diagnosis of  primary FSGS and HIVAN 
Method: The study group consisted of 31 children; HIVAN (n=11) and idiopathic FSGS 
(n=20). The control group consisted of 40 children with no kidney disease; HIV positive 
(n=20) and HIV negative (n=20). Serum samples were stored at -800C and were analysed for 
bFGF using the Bio-Plex ProTM Human Cytokine.  Statistical analysis was performed using 
GraphPad Prism version 5.  
 
xi 
 
Results: The concentration of bFGF was higher in the HIVAN (mean= 9.0 ng/ml; 95% CI: 
10.18 – 7.18) vs idiopathic FSGS (mean= 7.0 ng/ml; 95% CI: 8.16 – 6.59) (Mann-Whitney 
U= 66.5; p= 0.0685). There was a significant elevation of serum bFGF Mean Flourescence 
Intensity (MFI) in children with HIVAN when compared to controls [HIV positive (mean = 
7.0 ng/ml; 95% CI: 7.56 – 6.38) (Mann-Whitney U= 58.8 ; p= 0.004) and negative controls 
(mean= 6.5 ng/ml; 95% CI: 7.00-6.06) (Mann-Whitney U= 43.5 p= 0.029)].  There was no 
statistically significant differences in serum bFGF MFI between patients with HIVAN vs. 
idiopathic FSGS and between idiopathic FSGS vs. controls. 
Conclusion: This study demonstrated statistically significant difference between bFGF levels 
in children with HIVAN and controls, although it failed to distinguish statistically significant 
differences in bFGF levels between HIVAN and idiopathic FSGS. 
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 BACKGROUND AND LITERATURE REVIEW 
1.1 Basic fibroblast growth factor 
The fibroblast growth factor (FGF) family consists of 18 secreted ligands. These secreted 
ligands can be categorized into two subfamilies; the canonical FGFs (FGF1-10, 16-18 and 
20), and the hormone-like FGFs (FGF 19, 21 and 23) (Burgess and Maciag, 1989). FGFs are 
classified as paracrine, intracrine and endocrine FGFs based on their mode of action (Itoh et 
al., 2015) . Paracrine and endocrine FGFs are secreted signaling molecules acting through 
cell-surface FGF receptors (FGFRs) (Ornitz and Itoh, 2015). In comparison, several 
endocrine FGFs, require α-Klotho or β-Klotho as a cofactor for binding to FGFRs (Ornitz 
and Itoh, 2015).  
The phenotypes of endocrine FGF knockout mice demonstrate that FGF are involved in 
phosphate and vitamin D metabolism (Itoh et al., 2015). There is evidence to suggest that 
endocrine FGF have a pathophysiological role in genetic and metabolic diseases. Abnormal 
levels of endocrine FGF may serve as a potential risk factor for metabolic diseases but also 
are useful biomarkers for detection of metabolic diseases (Itoh et   al., 2015). These 
discoveries provide new perceptions into the physiological and pathophysiological roles of 
endocrine FGFs and their role as potential biomakers and therapeutic targets for metabolic 
diseases.  
FGF2, also known as basic fibroblast growth factor (bFGF) and FGF-β, is a growth 
factor and signaling protein encoded by the FGF2 gene (Dionne et al., 1990). It is synthesized 
primarily as a 155 amino acid polypeptide, resulting in an 18 kDa protein (Kim, 1998). Basic 
FGF as well as their receptors control certain key behaviours such as migration, 
differentiation, survival and proliferation (Brooks et al., 2012). Furthermore, bFGF 
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specifically promotes fibroblast proliferation and up-regulates the expression of proliferation-
associated genes (Strutz et al., 2000). 
1.1.1 Molecules that mediate the function of FGF 
The activated FGFs transfer their signals to cellular targets via four FGF receptors (FGFRs) 
(Ornitz and Itoh, 2016). A number of alternative splicing occur in different intracellular and 
extracellular encoding regions (Ornitz and Itoh, 2015). Furthermore, alternative splicing 
within the third immunoglobulin-like domain of FGFRs 1-3 generating b and c alternates are 
mainly important ligand binding specificity determinants. Remarkably, FGF1 is the only 
ligand that is capable of activating all FGFRs regardless of alternative splicing. It has been 
demonstrated by ligand binding specificity assays that the FGF7 subfamily specifically binds 
and stimulates a splice variant (Ornitz et al., 1996). Uniquely, the FGF9 subfamily also 
stimulates FGFR 3b. As for the canonical FGF subfamilies (FGF 1, 4, 7, 8, 9) heparan sulfate 
(HS) acts as the primary endogenous co-factor for the activation of the receptor as well as its 
ligand binding. Lastly, intracellular the FGFs subfamily specifically bind and mediate Nar 
channels without activating FGFRs (Ornitz and Itoh, 2016).  
Often FGF signals reciprocally and directionally through epithelial mesenchymal boundaries 
(Olsen et al., 2003). The functionality of these signaling pathways need exceedingly tight 
mediation of FGF activity as well as receptor specificity. Directional signaling mediates the 
patterning and outgrowth of a given compartment during development. Hence, differential 
expression of the receptors' alternate splice forms can inhibit or limit autocrine signaling 
(Olsen et al., 2003).  
1.1.2 Interaction with heparin or heparan sulfate 
One of the important features of FGF is its interaction with heparan sulfate proteoglycan 
(HSPG) (Ornitz and Itoh, 2016). These interactions are responsible for the stabilization of 
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FGFs to inhibit proteolysis and thermal denaturation; thereby strictly preventing their release 
and diffusion into interstitial spaces (Virag et al., 2007). Interaction between HS and FGFs 
lead to the formation of higher order oligomers and dimers (Nusayr et al., 2013). A study by 
(Schreiber et al., 1985)  demonstrated that HS increases the half-life and affinity of the FGF-
FGFR complex and that HS can bridge FGF 2 including the FGFR by attaching to a groove 
created by the heparan-binding sites of both the receptor and ligand.  
1.1.3 FGF in functional and structural kidney damage 
Recent studies have established the intrinsic capacity of the kidney to undergo repair 
subsequent to acute damage via re-expression or repair proteins (Villanueva et al., 2014). 
Initiation with bFGF could speed up this process. Nonetheless, there is not sufficient 
evidence  that supports whether bFGF can induce this phenomenon in damaged kidney cells 
(Villanueva et al., 2014). 
bFGF is a protein that is released for the induction of cellular aggregation (Karavanova et al., 
1996). The core effect of bFGF includes maintaining WT-1 synthesis, a transcription factor 
that is responsible for inducing the conversion of mesenchymal cells into metanephric tissue 
(Karavanova et al., 1996). Furthermore, bFGF is able to induce expression of repair proteins 
and speed up the process of repairing tissue when it is exogenously added or conversely, 
renal injury could be sustained when it is inhibited (Villanueva et al., 2008). Moreover, it has 
been established that bFGF stimulates the proliferation rate of kidney cells (Dudley et al., 
1995).  
Previous studies have recognized bFGF as a biomarker for renal disease, particularly in focal 
segmental glomerulosclerosis (FSGS), where they demonstrated significant levels of bFGF 
low affinity receptors in the kidney of HIV infected children (Ray et al., 1999). These studies 
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highlighted that bFGF in circulation is subsequently harboured in the kidney bound to HSPG 
(Klagsbrun and Baird, 1991). 
1.1.4 Progression of  kidney disease 
In both animal models and in humans with FSGS, glomerulosclerosis is categorized by 
scarring of small sections of individual glomeruli as well as tubular structure (D'Agati et al., 
2011). The glomeruli show loss of capillaries leading to localized areas of progressive 
scarring and cell proliferation that ultimately result in breaking down of the capillary bed 
(Klahr and Morrissey, 2000). Tubules, mainly those bound to scarred glomeruli, are shrunken 
and in most cases, are delimited by inflammatory cells (Mullins et al., 2016) . This is 
followed by activation and proliferation of matrix-producing fibroblasts, mainly bFGF which 
synthesize substantial amounts of extracellular matrix deposited in an organized manner 
(Klahr and Morrissey, 2000). Several studies have established that the differential expression 
of certain bFGFs is one of the key reasons for scar development (Klahr and Morrissey, 2000). 
Thus, bFGF may play an important role in the scarring process pathognomic to FSGS.  
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Figure 1: The pathophysiological processes linked to FSGS. (A) A healthy, normal kidney (left), and 
an enlarged view of the tubule its associated vasculature (right). (B) A chronically diseased kidney, 
displaying the progression of factors that lead to tubule-interstitial fibrosis (Mullins et al., 2016).  
 
1.2 Focal segmental glomerulosclerosis  
FSGS is one of the most common forms of steroid resistant nephrotic syndrome and is 
categorized histologically by obliteration of glomerular capillaries, mesangial sclerosis, foam 
cells, hyalinosis and adhesion between the Bowman’s capsule and glomerular tuft (Rood et 
al., 2012). It is a worldwide public health issue due to its increasing incidence and 
prevalence. Nephrotic patients with FSGS have a poor prognosis with 50% progressing to 
end stage renal disease (ESRD) over 3 to 8 years  (Korbet, 2000).  
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 FSGS may be primary or secondary to various causes including infections such as Human 
Immunodeficiency virus type I (HIV-1) (Kim et al., 2016). Over the past 20 years there has 
been a significant increase in the incidence of FSGS, particularly in adult patients where there 
has been a 2-3 fold rise in the rate of diagnosis of FSGS (Kiffel et al., 2011). A similar 
increase has been documented in children (Kiffel et al., 2011). Research has shown that 
majority of steroid resistant nephrotic syndrome is due to increasing levels of angiotensin II, 
which together with other growth factors, also up regulate the expression of basic fibroblast 
growth factors (bFGF) (Klahr and Morrissey, 2000). Hence, the development and progression 
of FSGS is determined by the action of these growth factors. FGFs are involved in the 
regulation of the balance between proliferation and cell growth versus apoptosis, necrosis and 
cell death as well as the balance of degradation against matrix accumulation (Fogo, 2015). 
Hence, glomerulosclerosis may result due to an increase in bFGF expression leading to the 
accumulation of extracellular matrix which contribute to renal malfunction (Fogo, 2015).  
In patients with FSGS, bFGF is up regulated (Strutz et al., 2000). This is supported by a 
study done on HIV positive children where elevated levels of bFGF were observed and this 
was explained by the fact that renal HSPG functions as a sink, trapping bFGF as well as other 
growth factors (Strutz et al., 2000).  
Globally, the incidence of FSGS has significantly increased over the past 30 years across all 
ethnic groups (Kiffel et al., 2011). It is one of the most significant clinical disorders that 
causes acquired chronic kidney disease (CKD) in both adults and children (Kiffel et al., 
2011). FSGS has been the subject of intensive basic medico-clinical studies because of the 
significant morbidity arising from this condition. It was initially diagnosed on kidney biopsy 
specimens taken from patients suffering from steroid resistant nephrotic syndrome (Kiffel et 
al., 2011). There is not significance data on the epidemiology of FSGS in many parts of 
Africa due to the unavailability of renal registries. In Africa, glomerular diseases have been 
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reported to account for a large proportion of patients.  Most renal biopsies reported from 
Africa originates from studies in North Africa (Okpechi et al., 2016). Of the 12,093 biopsies 
that were reported, 70% were from studies carried out in North Africa and these countries had 
more papers published after the year 2000 compared to countries from sub-Sahara Africa 
(Okpechi et al., 2016).  
Attempts have been made to establish a histological classification of renal pathology so as to 
predict pharmacological response and treatment. In most of the pathological scoring systems 
used worldwide, the scarring associated with FSGS is characterised into five categories; 
collapsing, perihilar, not otherwise specified (NOS), hypercellular, and tip lesions (D'Agati, 
2003). The intensity of mesangial cellularity can differ and there is continuing debate whether 
the severity of this observation has prognostic implications (Stokes et al., 2006). The 
collapsing variant, which is subtype of FSGS, has constantly been proven to be resistant to 
treatment and runs a severe to moderately aggressive course (Kiffel et al., 2011).  
Ultrastructural studies display occasional immune deposits, segmental scarring, and fusion of 
the podocyte foot process (Markowitz et al., 2003). Reticular inclusion bodies are observed 
on various secondary types of FSGS such as HIV nephropathy. Foot process effacement is 
often more severe and prevalent in primary FSGS than in secondary FSGS (Kiffel et al., 
2011). Immunofluorescence findings often display deposition of IgM and complement factor 
C3 in sclerotic portions but this is reflected as a non-specific finding (Jennette and Hipp, 
1985).  
1.2.1 Pathogenesis of focal segmental glomerulosclerosis  
Podocyte dysfunction is currently one of the central features in the pathogenesis  of FSGS 
(Barisoni et al., 2009). Podocyte dysfunction could be due to an inherent abnormality within 
the podocyte or an exogenous element that stimulates podocyte damage. Loss of  these non-
9 
 
proliferative terminally differentiated cells is also critical in the progression of FSGS (Kiffel 
et al., 2011). In vivo experimental models that categorise podocyte damage and loss, showed 
that podocytopenia is largely related with the histological pattern of damage (Wharram et al., 
2005). In  experiment models that were performed it was observed that, if ≤20% podocytes 
are lost, resident glomerular epithelial stem cells transit from a position adjacent to the 
Bowman’s space into the glomerulus to recover injured podocytes that were damaged by 
apoptosis and necrosis. However, if the loss is between 20-40%, FSGS lesions result, 
whereas if loss of podocyte is >40%, then there is global sclerosis of the glomerulus (Kiffel et 
al., 2011).  
Transformed expression of various signalling molecules are linked with podocyte damage 
and the progression of glomerulosclerosis in animal models of FSGS (Kaufman et al., 2010). 
These include Sidekick-1 and Notch proteins which play integral roles in the morphology of 
the glomerulus and normal nephrogenesis (Kaufman et al., 2010). Upcoming genomic studies 
may assist in determining the role of these as well as other molecules in the broad spectrum 
of disease severity that occur in FSGS patients.  
One of the interesting improvements that have been discovered in the past decade in 
understanding FSGS is the association between genetic mutations and several structural 
proteins of the podocyte (Kaufman et al., 2010). The first FSGS genetic studies revealed the 
occurrence of glomerulopathy in humans with  altered genes for podocin  included NPHS1, 
NPHS2, WT-1, LAMB2, CD2AP, TRPC6, ACTN4 and INF2 (Chen and Liapis, 2015). 
Furthermore, seven other genes have been demonstrated in FSGS family pedigrees which 
include; IFN2, CD2AP, α-actinin -4, laminin β2, Wilms tumor-1, phospholipase C epsilon 
(Kiffel et al., 2011). In addition, nephron protein mutations, which were initially 
demonstrated in connection with congenital nephrotic syndrome, can also result in steroid-
resistant nephrotic syndrome in adults and children (Philippe et al., 2008). Generally, there 
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are two forms of mutations, autosomal dominant disease with onset in adulthood or in late 
adolescence and an autosomal recessive pattern of inheritance seen mainly in children 
(Philippe et al., 2008). The incidence of sporadic FSGS cases related with each mutation 
differs from 3-20% depending on the patient cohort being tested. Current studies with 
genotype-phenotype correlations have simplified certain mutations that have an effect on the 
clinical course of disease in FSGS patients (Caridi et al., 2009). For instance, the NPHS2 
gene in podocin are related with onset of disease earlier in childhood and rapid progression to 
end stage kidney disease (Caridi et al., 2005).  
1.2.2 Therapy 
There is dearth of clinical information describing the outcome of randomized trials (RCT) in 
glomerular and nephrological diseases to guide treatment of FSGS (Leaf et al., 2010). All 
FSGS patients profit from the use of antiproteinuric agents that antagonize the renin-
angiotensin II-aldosterone axis(Kiffel et al., 2011). This therapy comprises inhibition of renin 
by specific renin antagonists, aldosterone antagonists, angiotensin converting enzyme 
inhibitors, and lastly angiotensin receptor blockers(Mercier et al., 2014). There is emerging 
recognition of the role of T-cells in the pathogenesis of the disease, and the successive focus 
on immunosuppressive agents as possible treatments may be misguided and delay the search 
for therapeutic agents targeting T-cells (Meyrier, 2009). This is supported by current data that 
cyclosporine may be responsible for reducing proteinuria in FSGS animal models by acting 
specifically on the podocyte and maintaining the actin cytoskeleton instead of aiming at 
immunological mechanisms, specifically inhibition of nuclear factor of triggered T-cell 
(NFA7)  (Meyrier, 2009).  
About 25% of FSGS patients have total or partial remission of proteinuria after a course of 
corticosteroids (Meyrier, 2009). One exception to this typical grim outcome is the feedback 
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from a single center signifying that almost 80% (18/23) of children suffering from FSGS may 
accomplish a thorough or partial remission over a mean continuation period of 46 ± 5 months 
in response to extended treatment with pulses doses of methylprednisolone (Mendoza et al., 
1990). Using oral dexamethasone pulses, Kopp et al (unpublished data) tried to duplicate this 
in adults; however the outcomes were not as encouraging as reported in children by (Kiffel et 
al., 2011). Hence, steroids are not consistently optimal therapy in FSGS patients. 
Furthermore, the major side effects of prolonged use of steroids significantly restricts its use 
in patients suffering from bone disease, hypertension, or those that are overweight (Meyrier, 
2009). 
The effectiveness of rituximab to encourage a remission in 25-40% of patients with steroid-
resistant FSGS suggests that B-cells rather than T-cells may be possible immunosuppressive 
therapy targets (Kiffel et al., 2011). Additionally, other therapies that could be utilized 
include, mycophenolate mofetil (MMF) which is one of the most commonly used 
immunosuppressive drugs used either alone or in combination with other immunosuppressive 
drugs (e.g. corticosteroids and/or calcineurin inhibitors) for the prevention of organ rejection 
after solid organ transplantation as well as in the therapy of autoimmune and neoplastic 
diseases (Oellerich et al., 2000, Allison and Eugui, 2000) .   
1.2.3 Adjunctive therapies for FSGS 
Several adjunctive therapies have been proposed in an attempt to reduce the progression of 
tissue injury in FSGS. These include angiotensin I-converting enzyme inhibitors, renin-
angiotensin-aldosterone, angiotensin receptor blockers (ARBs) and statins. However, these 
therapies have not displayed significant positive improvements specifically in tubular 
function and glomerular filtration rates that could prevent the final phase of renal disease 
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(Wolf et al., 2003). Hence, research for new promising and alternative treatments is one of 
the main concerns in nephrology.  
Statins are well known to decrease cardiovascular morbidity and mortality in patients with 
and without recognized cardiovascular disease as well as in several high-risk populations 
(Shepherd et al., 1995). Nonetheless, definite evidence for developed cardiovascular 
outcomes with statin therapy for renal disease is not yet available (Agarwal, 2007).  
The overall conclusion established from various FSGS researchers suggests that suitable 
pharmacological treatments for the development of renal fibrosis may require an approach 
that is multi-pharmacological (Kiffel et al., 2011). More research is required to understand 
the developmental role of bFGF and other FGFs as these will provide further insight as to 
whether a single or multiple FGFs interact during the progression of FSGS. The aim of this 
study is to investigate bFGF as an non-invasive biomaker to renal biopsy in children with 
primary FSGS and HIVAN compared to controls.  
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1.2.4 Aims and Objectives 
 
Aim  
The aim of this study was to investigate the use of  basic fibroblast growth factor (bFGF) as a 
non-invasive biomarker for the diagnosis of primary FSGS and HIVAN.  
Objectives 
1. To compare the levels of bFGF in children with biopsy proven FSGS to healthy 
controls.  
2. To measure and compare the levels of  bFGF in FSGS according to HIV status. 
3. To compare the levels of bFGF in FSGS and HIVAN to HIV positive children with no 
kidney disease and healthy controls. 
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Abstract 
Background: The human immunodeficiency virus (HIV) infection can lead to the 
development of HIVAN with the majority of patients progressing to end-stage kidney 
disease. Importantly, individuals of African ancestry are more at risk of developing HIVAN 
than their European descent counterparts. Early diagnosis and immediate nephrology referral 
are key steps in management because this enable predialysis education, allows for 
implementation of preventive measures that delay or even halt progression of HIVAN to end-
stage kidney disease, as well as decrease morbidity and mortality. Currently, the diagnosis of 
HIVAN requires a kidney biopsy. Due to the development of genomics, epigenetics, 
transcriptomics, proteomics, and metabolomics, the introduction of novel techniques will 
allow for the identification of novel biomarkers in kidney diseases. Previous studies have 
recognized basic fibroblast growth factor (bFGF) as a biomarker for HIVAN, since 
significant levels of bFGF low affinity receptors have been previously found in the kidneys 
from HIV infected children. bFGF is an angiogenic growth factor that is involved in kidney 
growth and the pathogenesis of kidney diseases.  
The aim of this study was to investigate the use of  basic fibroblast growth factors (bFGF) as 
a non-invasive biomarker for the diagnosis of FSGS in HIV positive (HIVAN) and HIV 
negative children (primary FSGS). 
Method: The study group consisted of 31 children; HIVAN (n=11) and idiopathic FSGS 
(n=20). The control group consisted of 40 children with no kidney disease; HIV positive 
(n=20) and HIV negative (n=20). Serum samples were stored at -800C and were analysed for 
bFGF using the Bio-Plex ProTM Human Cytokine.  Statistical analysis was performed using 
GraphPad Prism version 5.  
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Results: The concentration of bFGF was higher in the HIVAN (mean= 9.0 ng/ml; 95% CI: 
10.18 – 7.18) vs idiopathic FSGS (mean= 7.0 ng/ml; 95% CI: 8.16 – 6.59) (Mann-Whitney 
U= 66.5; p= 0.0685). There was a significant elevation of serum bFGF Mean Flourescence 
Intensity (MFI) in children with HIVAN when compared to controls [HIV positive (mean = 
7.0 ng/ml; 95% CI: 7.56 – 6.38) (Mann-Whitney U= 58.8 ; p= 0.004) and negative controls 
(mean= 6.5 ng/ml; 95% CI: 7.00-6.06) (Mann-Whitney U= 43.5 p= 0.029)].  There was no 
statistically significant differences in serum bFGF MFI between patients with HIVAN vs. 
idiopathic FSGS and between idiopathic FSGS vs. controls. 
Conclusion: This study demonstrated statistically significant difference between bFGF levels 
in children with HIVAN and controls, although it failed to distinguish statistically significant 
differences in bFGF levels between HIVAN and idiopathic FSGS. 
 
Keywords: HIV, HIVAN, bFGF, FSGS 
Running title: FGF levels in HIV associated nephropathy 
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Introduction 
Human immunodeficiency virus (HIV) infected antiretroviral therapy naïve children display a 
high viral load during the late phase of infection, placing them at risk of developing several 
types of kidney diseases, including HIV associated nephropathy (HIVAN) [1]. However 
children on antiretroviral therapy, kidney disease is usually uncommon [2]. The spectrum of 
kidney disease that occurs with HIV infection includes acute kidney injury, disorders of 
tubular function, thrombotic microangiopathies, kidney injury secondary to drug use and 
various forms of chronic glomerular diseases including HIVAN and HIV associated immune 
complex disorders [3] . The classical findings of HIVAN include: persistent proteinuria 
usually accompanied by varying degrees of haematuria, urinary sediment with urinary 
microcysts, azotemia, normal to large kidneys on ultrasound images, normal blood pressure, 
and focal segmental glomerulosclerosis (FSGS) on kidney biopsy findings [4,2]. During HIV 
infection, FSGS is an important comorbidity [5].  
FSGS is a primary cause of nephrotic syndrome in children, and if untreated, has a poor 
prognosis [6]. Nonetheless, the pattern of segmental and focal sclerosis is not specific to 
disease with the primary podocyte lesions, and several other diseases e.g. HIVAN, 
demonstrate light microscopic lesion patterns such as overlying cell hyperplasia as well as 
glomerular tuft injuries similar to primary FSGS [7].  
In the pre-antiretroviral therapy era, HIVAN was characterized by rapid progression to end-
stage kidney disease leading to the need for dialysis [8]. Highly active antiretroviral therapy 
(HAART) has improved the natural course of this disease, increasing the importance of early 
diagnosis and allied suitable care [8]. Robust biomarkers may assist in diagnosing and 
monitoring kidney disease commencing from initial stages of the disease [9]. Previous studies 
have recognized bFGF as a biomarker for FSGS, since significant levels of bFGF low affinity 
receptors have been previously found in the kidney of HIV infected children [10]. bFGF is an 
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angiogenic vascular growth factor, that is essential for cellular aggregation induction [11]. It 
is involved in the stimulation of epithelial condensation, apoptosis inhibition as well as 
maintenance of WT-1 synthesis [12]. Furthermore, bFGF is mainly stored as an inactive pool 
within the extracellular matrix and vessel wall, and is absent in the circulation unless it is 
secreted during tissue injury and angiogenesis [13]. Elevated levels of bFGF may result  in 
the progression of FSGS, and unrestrained elevation of bFGF in the kidney extracellular 
matrix can generate the fibrotic lesions and tubulointerstial proliferative distinctive to 
HIVAN [13]. However, the processes that regulate secretion and behaviour of bFGF in 
glomeruli and renal tubules are as yet not clearly understood [14]. 
Based on the findings that elevated bFGF may result in the progression of FSGS and plays a 
role in the generation of fibrotic lesions and tubulintersitial proliferation distinct to HIVAN, 
our aim was to determine if bFGF can be used as a non invasive biomarker for the detection 
of HIVAN and idiopathic FSGS.  
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Method and Materials 
Ethical consideration 
This study was performed on blood samples collected from Black African children with 
idiopathic FSGS and HIVAN aged between 1-16 years. Ethical approval was received from 
the University of KwaZulu-Natal Biomedical Research Ethics Committee (BREC 220/17) 
and permission to perform the project was given by the Hospital managers at Inkosi Albert 
Luthuli Central Hospital and King Edward VIII Hospital. Furthermore, written informed 
consent was obtained from the children’s parents or legal guardian prior to collection of 
blood samples.  All identifies were removed and following collection, each blood sample was 
assigned a study identity number to maintain anonymity. All data collected from the hospital 
records on a Microsoft Excel spreadsheet using Windows (version 7)® was protected by a 
password only known by the researchers.  
Diagnosis of HIVAN 
The diagnosis of HIVAN was made following confirmation of HIV-1 infection and presence 
of persistent proteinura ≥1+ on urinary dipstick examination (on at least 3 separate occassions 
in non-febrile children) with one or more of the following: (i) presence of enlarged echogenic 
kidneys by renal ultrasound; (ii) abnormal urinary sediment; (iii) microcystic tubular dilation, 
a childhood variant of HIVAN in the absence of significant podocyte lesions; and (iv) 
histological finding of FSGS [23]. 
Creatinine measurement 
Serum samples were analysed for creatinine using the modified Jaffe kinetic method on the 
Siemens Advia 1800 analyser (Siemens Healthcare Diagnostics, Tarrytown, USA),  The 
revised Schwartz equation was used to estimate GFR using the equation [24]. 
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Revised Schwartz GFR 
= 36.5 x height in cm 
creatinine in (umol/l) 
 
The study population 
Black South African children aged between 1-16 years from KwaZulu-Natal were recruited. 
The study population included children with biopsy proven HIVAN (n = 11) and idiopathic 
FSGS (n =20). A control group (n= 40) was further stratified based on the HIV status i.e., 
HIV positive children with no kidney disease (n = 20) and HIV negative children with no 
kidney disease (n = 20).  
Inclusion criteria for HIVAN group 
Black South African children with HIV-associated biopsy-proven nephropathy (FSGS) aged 
between 1-16 years old who gave written in formed consent for participation in the study. 
Exclusion criteria for HIV Associated FSGS (HIV positive) group 
HIV negative Black South African with histological forms of HIV related nephropathy other 
than FSGS, children <1 year old, failure to obtain written informed consent for participation 
in the study, absence of kidney biopsy or inadequate tissue for histology. 
Inclusion criteria for idiopathic FSGS (HIV Negative) group 
Black South African children with biopsy-proven idiopathic FSGS aged between 1-16 years 
old with written informed consent for participation in the study. 
Exclusion criteria for idiopathic FSGS (HIV Negative) group 
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HIV negative Black South African children between 1-16 years old with idiopathic nephrotic 
syndrome having histological forms of nephropathy other than FSGG, children <1 year old, 
failure to obtain written informed consent for participation in the study, or inadequate tissue 
for histology. 
Inclusion criteria for control group 
HIV negative and positive Black South African children between the ages of 1-16 years with 
no kidney disease.  
Exclusion criteria for control group 
Black South African children with FSGS or other kidney diseases and children below the age 
of 1 year or over 16 years. 
Bioplex Immunoassay 
Serum from stored samples were analysed for bFGF using the quantitative BioPlex ProTM 
Human Cytokine. Briefly, samples as well as the standards were diluted using the Bioplex 
sample diluent HB and standard diluent HB, respectively. Coupled beads were added into 
each well of the 96 well assay plate, and a sealing tape was used to protect the beads from 
light. Using 100 µl of assay buffer, the plate was washed and left to incubate at 850 rpm at 
room temperature (RT).  With 10 min left in the incubation, the detection antibodies were 
vortexed and added to each well, followed by a second incubation at 850 rmp at RT. To 
complete the reaction an addition of fluorescent conjugate streptavidin-phycoerythrin (SAPE) 
was added to the wells prior to incubation of the plate at RT. After the final wash, beads were 
resuspended in 125 µl assay buffer. 
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Analysis 
Samples were analysed on Bio-plex MAGPIXTM Multiplex system (Bio-Rad laboratories 
Inc., USA) and the data was obtained using the Bio-Plex ManagerTM version 4.1 software. A 
standard curve was generated using the known concentration (ng/ml) of each analyte by 
plotting the median fluorescent intensity (MFI) signal against concentration39. These 
standards were used to interpolate the concentration of the unknown samples. Intra-plate 
variability were determined with CV ˂20% and ( ) between 70-
130% (r=0.8, p=0.05). The data was imported into an Excel spreadsheet for statistical 
analysis. 
Statistical analysis 
Data was entered into SPSS version 24 (Statistical Packages for the Social Sciences) and 
GraphPad Prism version 5 (GraphPad software version 5, San Diego, Califonia, USA) for 
analysis. A p value <0.05 was considered as statistically significant. A descriptive statistical 
analysis of the data (means, standard deviations, ranges, frequencies and percentages, etc.) 
were initially conducted prior to inferential analysis. The independent samples T-Test test 
and Anova were used to determine if high levels of bFGFs are associated with the 
development of FSGS. The Chi-square test of association was used to assess any associations 
between categorical variables. 
Results 
Patient demographics and Clinical Characteristics  
The overall study population was inclusive of 71 children, 31 of whom had a 
histopathological pattern of FSGS. A summary of the patients’ demographics are outlined in 
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Table 1. The mean age for idiopathic FSGS and HIVAN was (9 ± 3.11 years) and (10 ± 3.62 
years) respectively.  
To evaluate associations with the variability, bFGF concentration was compared with urea, 
cholesterol, eGFR, CD4, age, weight and creatinine. Non-significant statistical correlations 
were demonstrated, therefore signifying that these demographic data had no observable effect 
on the bFGF MFI in children.  
The Fluorescence Intensity (FI) of bFGF  
The serum FI of bFGF is displayed in figures 1 – 7. 
There was a significant elevation of serum bFGF MFI in children with HIVAN when 
compared to the HIV  positive  (mean = 7.0 ng/ml; 95% CI: 7.56 – 6.38) (Mann-Whitney U= 
58.8 ; p= 0.004) and HIV negative (mean= 6.5 ng/ml; 95% CI: 7.00-6.06) (Mann-Whitney 
U= 43.5 p= 0.029) control groups. There was no statistically significant difference between 
children with idiopathic FSGS vs positive and negative controls.  
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Discussion 
Several studies have confirmed the presence of HIVAN in children who are most likely to 
develop nephrotic syndrome in association with FSGS [10]. This study reports a significant 
elevation of serum bFGF MFI in children with HIVAN when compared to the HIV positive  
and HIV negative control groups (p = 0.0043). Similarly a study by Liu et al.  detected 
elevated levels of bFGF in HIVAN children [13]. HIVAN is associated with an increased 
expression of renal HSPGs that may facilitate the accumulation of bFGF in the kidney and 
the progression to end-stage kidney disease. Additionally, renal tubular epithelial cells 
harvested from the serum of children with HIVAN produce and release high levels of bFGF, 
as well as a FGF-binding protein, that facilitates the release of several members of the FGF’s 
family, including bFGF [13]. These findings may explain the elevated levels of serum bFGF 
in children with HIVAN. However, our study demonstrated no significant difference in 
paediatric bFGF between HIVAN versus idiopathic FSGS. 
Furthermore, we noted higher albumin levels in HIVAN children compared to primary FSGS 
children. These results corroborate findings that suggest increased levels of albumin result 
from improved appetite and general well-being as well as decreased loss of protein in the 
urine. Proteinuria is a marker of HIV nephropathy and has been correlated with decreased 
renal function and progression to ESRD [14]. It must be noted that in our study all HIV 
infected children were on HAART treatment. HAART therapy and angiotensin-converting 
enzyme antagonists are highly effective in reducing proteinuria and protecting renal function 
[15]. 
In our study high levels of cholesterol and creatinine together with reduced eGFR were found 
in children with idiopathic FSGS compared to children with HIVAN. These parameters 
further support the view that children with HIV-associated FSGS treated with HAART may 
achieve full remission and delay or prevent progression to end-stage kidney disease. Such 
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findings are supported by a study on 152 biopsy proven HIVAN patients treated with 
HAART that were found to have better renal survival compared with patients who did not 
receive HAART. Hence, HIVAN should be considered as an indication to initiate HAART 
[16]. 
In our study, the bioactive protein, bFGF was significantly lower in HIV negative  and 
positive controls compared to HIVAN children. The possible reason for the significantly 
raised bFGF in children with HIVAN compared to HIV positive and negative controls 
includes stimulation of cell growth by bFGF [17] [18]. High levels of bFGF may lead to the 
development of FSGS [13]. bFGF can increase the attachment of HIV-infected mononuclear 
cells to renal epithelial cells [19], enhance the expression of hypoxia-inducible genes in these 
cells [14], induce renal microcysts [20], and/or cause FSGS [21]. Excessive accumulation of 
bFGF in the  renal extracellular matrix can induce tubulointerstitial proliferative and fibrotic 
lesions typical of HIVAN [13]. However, the mechanisms that control the release and activity 
of bFGF in renal tubules and glomeruli are not clearly described. 
This study was based on previous studies displaying an advanced accumulation of heparin-
binding growth factors in association with the occurrence of the renal microcytic tubular 
lesions that are biomarkers for children with HIVAN [18]. Another study that was done based 
on this approach that  revealed significant differences in the levels of bFGF between HIVAN 
and the control group, with bFGF showing elevation. In support of the latter finding, our 
study also reports similar results [22].  
In our study, no significant difference was observed between idiopathic FSGS vs. HIV 
positive and negative controls as well as between children having idiopathic FSGS vs. 
HIVAN. This lack of significant differences in bFGF levels between HIVAN study group and 
controls may be  also be attributed to the small sample size that was used in our study or that 
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our patients had established disease and were on treatment, with arrested or markedly 
attenuated distal tubular cell injury. 
Our study and that of Wyatt [19], demonstrate that bFGF can be used as a potential candidate 
renal biomarker for HIVAN. However, further studies in a larger cohort of children are 
necessary to validate these data. It is also essential to examine other new biomarkers for 
HIVAN as an approach to making a more conclusive diagnosis of HIVAN [24].   
There are several other limitations to our study. Samples were collected and stored at -800C 
to prevent protein degradation until further use. It is likely that during the storage periods, 
there was a decrease of the serum proteins due to protein degradation. This could have led to 
the non-significant differences in serum levels of bFGF. Moreover, this study only included a 
homogenous group of Black African children and may therefore not be applicable to other 
population groups. Children recruited for the study were on treatment and this could have had 
an impact on the levels of serum levels of bFGF studied.  
From the observations of the study the serum profile of bFGF was the highest in HIVAN, 
followed by idiopathic FSGS, and HIV positive controls, with lowest level found in HIV 
negative controls. The significant difference between bFGS in children with HIVAN 
compared to controls suggests that bFGF may be a useful biomarker in distinguishing 
HIVAN from HIV positive children with no kidney disease. In HIV-infected children, one 
can minimize the risk of developing kidney disease by beginning  antiretroviral therapy early 
in the course of the disease and continue with the treatment. bFGF could be used as an 
adjunctive marker for the detection of kidney disease in HIV infected children although this 
study did not address the sensitivity or specificity of bFGF against proteinuria or 
microalbuminuria or other biomarkers for the early detection of HIVAN. 
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Conclusion  
This study demonstrated statistically significant difference between bFGF levels in children 
with HIVAN and controls, although it failed to distinguish statistically significant differences 
in bFGF levels between HIVAN and idiopathic FSGS. Further studies with a larger samples 
size are required to assess the role of bFGF as a potential biomarker for the detection of 
HIVAN in children.  
30 
 
Acknowledgement  
We appreciatively acknowledge the patients that consented to participate in this study, to 
King Edward VIII Hospitals and Inkosi Albert Luthuli nurses for their assistance during the 
sample collection. We would also like to thank the Optics and Imaging Centre at DDMRI of 
Nelson R Mandela School of Medicine in South Africa, for the use of the Bioplex equipment.  
Funding 
The authors would like to thank the College of Health Science UKZN and National Research 
Foundation, for financial support.  
 
 
 
 
 
31 
 
References  
1. SOLER-GARCÍA, Á. A., RAKHMANINA, N. Y., MATTISON, P. C. & RAY, P. E. 2009. A 
urinary biomarker profile for children with HIV-associated renal diseases. Kidney 
international, 76, 207-214. 
 
2. KALAYJIAN, R. C. 2010. The treatment of HIV-associated nephropathy. Advances in 
chronic kidney disease, 17, 59-71. 
 
3. BHIMMA, R., PURSWANI, M. U. & KALA, U. 2013. Kidney disease in children and 
adolescents with perinatal HIV‐1 infection. Journal of the International AIDS Society, 16. 
 
4. WYATT, C. M. & KLOTMAN, P. E. 2009. HIV-associated nephropathy. Genetic Diseases 
of the Kidney. Elsevier. 
 
5. HUSAIN, N. E., AHMED, M. H., ALMOBARAK, A. O., NOOR, S. K., ELMADHOUN, W. 
M., AWADALLA, H., WOODWARD, C. L. & MITAL, D. 2018. HIV-Associated 
Nephropathy in Africa: Pathology, Clinical Presentation and Strategy for Prevention. Journal 
of clinical medicine research, 10, 1. 
 
6. ROY, S. & STAPLETON, F. B. 1987. Focal segmental glomerulosclerosis in children: 
comparison of nonedematous and edematous patients. Pediatric Nephrology, 1, 281-285. 
 
7. KIFFEL, J., RAHIMZADA, Y. & TRACHTMAN, H. 2011. Focal segmental 
glomerulosclerosis and chronic kidney disease in pediatric patients. Advances in chronic 
kidney disease, 18, 332-338. 
 
8. RÖLING, J., SCHMID, H., FISCHEREDER, M., DRAENERT, R. & GOEBEL, F. 2006. 
HIV-Associated Renal Diseases and Highly Active Antiretroviral Therapy—Induced 
Nephropathy. Clinical Infectious Diseases, 42, 1488-1495. 
 
9. SONI, S. S., RONCO, C., KATZ, N. & CRUZ, D. N. 2009. Early diagnosis of acute kidney 
injury: the promise of novel biomarkers. Blood purification, 28, 165-174. 
 
10. RAY, P. E., LIU, X.-H., XU, L. & RAKUSAN, T. 1999. Basic fibroblast growth factor in 
HIV-associated hemolytic uremic syndrome. Pediatric Nephrology, 13, 586-593. 
 
11. KOPP, J. B. 2000. BMP receptors in kidney. Kidney international, 58, 2237-2238. 
 
12. KOPP, J. B., SMITH, M. W., NELSON, G. W., JOHNSON, R. C., FREEDMAN, B. I., 
BOWDEN, D. W., OLEKSYK, T., MCKENZIE, L. M., KAJIYAMA, H. & AHUJA, T. S. 
2008. MYH9 is a major-effect risk gene for focal segmental glomerulosclerosis. Nature 
genetics, 40, 1175. 
 
13. LIU, X.-H., AIGNER, A., WELLSTEIN, A. & RAY, P. E. 2001. Up-regulation of a 
fibroblast growth factor binding protein in children with renal diseases. Kidney international, 
59, 1717-1728. 
32 
 
 
 
14. VILLANUEVA, S., CONTRERAS, F., TAPIA, A., CARREÑO, J. E., VERGARA, C., 
EWERTZ, E., CESPEDES, C., IRARRAZABAL, C., SANDOVAL, M. & VELARDE, V. 
2013. Basic fibroblast growth factor reduces functional and structural damage in chronic 
kidney disease. American Journal of Physiology-Renal Physiology, 306, F430-F441. 
 
 
15. FREDRICK, F., FRANCIS, J. M., RUGGAJO, P. J. & MARO, E. E. 2016. Renal 
abnormalities among HIV infected children at Muhimbili National Hospital (MNH)—Dar es 
Salaam, Tanzania. BMC nephrology, 17, 30. 
 
16. LU, T.-C. & ROSS, M. 2005. HIV-associated nephropathy: a brief review. The Mount Sinai 
journal of medicine, New York, 72, 193-199 
 
 
17. OLAWUMI, H. & OLATUNJI, P. 2006. The value of serum albumin in pretreatment 
assessment and monitoring of therapy in HIV/AIDS patients. HIV medicine, 7, 351-355. 
 
18. ATTA, M. G., GALLANT, J. E., RAHMAN, M. H., NAGAJOTHI, N., RACUSEN, L. C., 
SCHEEL, P. J. & FINE, D. M. 2006. Antiretroviral therapy in the treatment of HIV-
associated nephropathy. Nephrology Dialysis Transplantation, 21, 2809-2813. 
 
19. WYATT, C. M. 2017. Kidney disease and HIV infection. Topics in antiviral medicine, 25, 
13. 
 
20. KLAHR, S. & MORRISSEY, J. J. 2000. The role of vasoactive compounds, growth factors 
and cytokines in the progression of renal disease. Kidney International, 57, S7-S14.  
 
21. TANG, P., JEREBTSOVA, M., PRZYGODZKI, R. & RAY, P. E. 2005. Fibroblast growth 
factor-2 increases the renal recruitment and attachment of HIV-infected mononuclear cells to 
renal tubular epithelial cells. Pediatric Nephrology, 20, 1708-1716. 
 
22. LI, Z., JEREBTSOVA, M., LIU, X.-H., TANG, P. & RAY, P. E. 2006. Novel cystogenic role 
of basic fibroblast growth factor in developing rodent kidneys. American Journal of 
Physiology-Renal Physiology, 291, F289-F296. 
 
23. RAMSURAN, D., BHIMMA, R., RAMDIAL, P. K., NAICKER, E., ADHIKARI, M., DEONARAIN, J., 
SING, Y. & NAICKER, T. 2012. The spectrum of HIV-related nephropathy in children. Pediatric 
nephrology, 27, 821-827. 
 
24. SCHWARTZ, G. J., MUNOZ, A., SCHNEIDER, M. F., MAK, R. H., KASKEL, F., WARADY, B. A. & 
FURTH, S. L. 2009. New equations to estimate GFR in children with CKD. Journal of the 
American Society of Nephrology, 20, 629-637. 
 
 
 
 
33 
 
 
0
5
10
15
HIVAN
Idiopathic FSGS
HIV positive control
HIV negative control
bF
G
F 
M
FI
*
*
**
Study Groups
 
 
Figure 1: The FMI (median and interquartile) of bFGF in HIVAN, idiopathic FSGS, HIV positive 
and HIV negative control groups. Serum MFI of bFGF was statistically different between the study 
groups, p = 0.003. 
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Figure 2: Serum MFI between HIVAN and idiopathic FSGS groups. Result are presented as median 
and interquartile range. Serum MFI between the two groups are not significantly different, p = 0.068. 
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Figure 3: Serum MFI between HIVAN and HIV positive control group. Result are presented as 
median and interquartile range. Serum MFI between the two groups was significantly different, p = 
0.004. 
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Figure 4: Serum MFI between HIVAN and HIV negative control group. Result are presented as 
median and interquartile range. Serum MFI between the two groups was significantly different, p = 
0.028. 
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Figure 5: Serum MFI between Idiopathic FSGS and HIV positive control group. Result are presented 
as median and interquartile range. Serum MFI between the Idiopathic FSGS and HIV positive group 
was observed to be not significantly different, p = 0.702. 
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Figure 6: Serum MFI between Idiopathic FSGS and HIV negative control group. Result are presented 
as median and interquartile range. No statistical significant was observed between the two groups, p = 
0.181.  
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Figure 7: Serum MFI between HIV positive and HIV negative children control groups. Result are 
presented as median and interquartile range. Serum MFI are not significantly different between the 
HIV positive and HIV negative control groups, p = 0.318.  
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Table 1: Clinical and laboratory demographics of patients, expressed as mean ± standard  
deviation 
 
 
 
HIVAN - Human immunodeficiency virus associated nephropathy 
FSGS  - Focal segmental glomerulosclerosis 
 
 
 
 
 HIVAN 
n = 14 
Primary FSGS 
n = 20 
HIV Positive  
Control 
n = 20 
HIV Negative 
Control 
n = 20 
Age  (years) 10 ± 3.62 9 ± 3.11 11 ± 3.25 7 ± 3.87 
Weight (kg) 31.13 ± 11.57 29.04 ± 10.33 37.25 ± 13.73 18.20 ± 10.55 
     
Creatinine 
(µ/mol) 
82.83 ± 62.36 45.32 ± 15.44 40.10 ± 9.25 29.14 ± 9.25 
Protein:creatinine 
ratio 
3.07 ± 2.04 4.22 ± 4.21 - 1.85 ± 0.67 
eGFR (ml/ min 
/1.73m2) 
119.98±57.84 125.09±102.53 207.13±58.02 218.00±122.01 
     
Urea blood 
(mmol/l) 
5.30 ± 4.26 7.64 ± 7.02 5.34 ± 9.81 2.71 ± 1.58 
Albumin (g/l) 29.91 ± 14.76 28.96 ± 7.96 30.77 ± 10.94 37.30 ± 9.25 
Cholesterol 
(mmol/l) 
4.82 ± 2.36 8.21 ± 4.80 3.75 ± 0.68 - 
CD4 count 820.20±642.10  900.60±620.00  
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SYNTHESIS 
Human Immunodefiency Virus (HIV) is a disease that raises serious concerns nationwide, 
with a prevalence of about 8% (Olawumi and Olatunji, 2006). In HIV infected patients,  
nephropathy is a common outcome (Röling et al., 2006). Direct influence of HIV has a 
substantial role in the development of HIV-associated nephropathy (HIVAN) (Röling et al., 
2006). HIVAN is commonly related with rapid progression to end-stage kidney disease 
(ESKD), occurring in persons who are newly diagnosed with advanced HIV infection (Wyatt 
et al., 2007). It has a discrete histology demonstrating a collapsing arrangement of focal 
segmental glomerulosclerosis (FSGS) (Wyatt et al., 2007). HIVAN pathogenesis involves 
local HIV infection of the kidney, with the virus causing injury to the glomerular and tubular 
epithelial cells (Wyatt et al., 2007). FSGS accounts for nearly 20% of incidence of the 
nephrotic syndrome in children, with Black children showing a unique susceptibility (D'Agati 
et al., 2011).  
Kidney biopsy is the only conclusive approach of establishing a diagnosis (Soler-García et 
al., 2009), but given the complication of performing this procedure in HIV-infected children, 
biomarkers  should be investigated. Basic fibroblast growth factor (bFGF) is a growth factor 
and signaling protein encoded by the FGF2 gene (Dionne et al., 1990). It is an angiogenic 
growth factor that participates in kidney injury and in the pathogenesis of kidney disease (Liu 
et al., 2001).  
This study describes the role of bFGF as a potential biomarker in the  detection of FSGS in 
HIV positive and negative children. We noted high levels of bFGF in children with HIVAN 
compared to HIV negative and HIV positive controls (with no kidney disease). These 
findings when compared with previously published studies of HIVAN in children suggest 
that bFGF may have a significant clinical role for the detection of FSGS in HIV infected 
children. Current studies have displayed the crucial role of biologically active bFGF in the 
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pathogenesis and development of kidney disease. Liu et al., found high levels of bFGF in the 
kidney and circulation of HIV-transgenic mice; HIV infected children with renal disease (Liu 
et al., 2001), which was also demonstrated in our study. These findings suggest that bFGF is 
released into the systemic circulation and renal interstitium by injured endothelial and renal 
epithelial cells, and that it may play a role in the pathogenesis of hemolytic-uremic syndrome 
and HIV nephropathy (Liu et al., 2001). 
The present study observed an increase of bFGF in HIVAN affected children in contrast to 
the levels of bFGF in controls. In healthy persons, bFGF is identified in glomerular 
Bowman’s capsule and the wall of blood vessels, with minimal staining covering the renal 
extracellular matrix (Ray et al., 1999). Over the years, several studies have supported this 
notion such as the one done by Soler-Garcia et al that showed levels of bFGF were higher in 
patients with HIVAN in contrast to those without  kidney disease (Soler-García et al., 2009). 
Furthermore, comparable outcomes were observed in HIV-Tg 26 mice correlating to these 
findings (Soler-García et al., 2009). Nonetheless, in HIVAN kidneys, bFGF was excessively 
high in the renal glomeruli (Soler-García et al., 2009). Rall et al discovered high circulating 
and renal tissue levels of bFGF in children suffering from acute stages of renal disease (Rall 
et al., 1985). Consequently, these findings further upkeeps the theory that bFGF released by 
injured glomerular endothelial cells amass in the HIVAN kidneys leading to renal cell death. 
Despite the knowledge that has been accumulated, up until now there is still insufficient data 
to support how bFGF becomes solubilized and hence activated in the human kidney (Liu et 
al., 2001). There is a possibility that bFGF solubilisation occurs from the digestion of the 
glycosaminoglycan portion of the cells attachment molecule by heparanases, released by 
blood monoclear cells which in turn activate bFGF (Moscatelli, 1992). Another possibility 
could be digestion of the protein backbone HPSG by proteases thus releasing bFGF from the 
immobilized state resulting to its activation (Yayon et al., 1991). However, at present it is 
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still unclear to what extent proteases and heparanases exert for the release of bFGF in the 
kidney (Liu et al., 2001). bFGF is  expressed more in children kidneys than in adults; 
vascular lesions are a crucial part of the immunodeficiency syndrome pathogenesis, even if 
HIVAN is not present (Ray et al., 1999). Therefore bFGF is possibly released during this 
process resulting in substantial levels of bFGF in HIV infected children.  
In vitro studies done in renal tubular epithelial cells collected from HIVAN children 
demonstrated that not a lot of colonies are positive for HIV-1, these findings strongly support 
that other mitogenic factors acting in relation with HIV-1 should be accountable for 
enhancing the tubule-intestitial proliferative lesions characteristic of HIVAN (Ray, 2009). 
For instance, renal tubular epithelial cells collected from children with HIVAN accumulate 
and release substantial amount of heparin-binding growth factors such as FGF-binding 
protein (BP-) that increase the release and mitogenic activity of some FGF family members 
(Ray et al., 2006). Since high levels of bFGF have been associated with HIVAN in children, 
bFGF released into the circulation could be confined in damaged renal cells attached to renal 
heparin sulphate proteoglycans (HSPG) (Ray, 2009). In this way, bFGF can enhance the 
binding of HIV infected monoclear cells to renal epithelial cells, increase the hypoxia-
inducible gene expression in these cells, and enhance renal microcysts and lead to HIVAN 
development (Ray, 2009). Moreover, HPSG has the ability to function as low-affinity 
receptors for the accumulation of HIV-1 including other heparin binding factors (Roderiquez 
et al., 1995). In support of this hypothesis, HIVAN children and HIV-Tg26 mice with kidney 
failure demonstrate a significant renal HSPG up-regulation which correlates with their kidney 
disease progression and the enhancement of heparin-binding growth factors (Ray et al., 
2004). Hence, the substantial release and up-regulated level of bFGF in HIVAN children may 
enhance tubular proliferative lesions as well as the aberrant renal tubular regenerative 
response (Ray, 2009).  
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In this study, all HIV infected children with the kidney disease were undergoing antiretroviral 
therapy hence their CD4 counts, albumin and creatinine levels were well stabilized  despite a 
slightly reduced eGFR compared to children with idiopathic FSGS or controls. These results 
suggest that antiretroviral therapy preserves kidney function in HIV infected and HIVAN 
patients. Another study found significant positive correlations between albumin and CD4 
count (Olawumi and Olatunji, 2006). (Olawumi and Olatunji, 2006). Albumin has also 
demonstrated to be a good index of severity of disease because albumin correlates well with 
CD4 cell count which are traditional indices of severity (Olawumi and Olatunji, 2006). 
Furthermore, studies in developed countries have displayed consistent results of mean levels 
of albumin correlating with decreasing of CD4 cell count (Shah et al., 2007). 
Even though the new anti-retroviral therapies have improved the health of HIV infected 
children, it has still not been established how they will influence the prevalence and outcome 
of HIVAN (Ray et al., 2004). The most  effective treatment for both HIV-infected patients 
with chronic kidney disease is HAART. HAART has been found to  delay progression to 
ESKD in African American patients by 38% (Röling et al., 2006). Even though there is 
strong supportive data of HAART as an effective therapy for HIVAN, no controlled, 
prospective,  randomized trials are available to support a positive influence of HAART on the 
outcome of HIVAN  (Röling et al., 2006).  
In summary, diagnosis of HIVAN requires performing a kidney biopsy, an invasive 
procedure, that has associated risks in HIV infected children. Also kidney biopsy  represents 
only a small portion of the kidney which  may not accurately represent the disease if it is is 
not homogenously spread throughout the kidney. Therefore, the need for non-invasive 
biomarkers as a complementary test in the diagnosis of glomerular diseases such as FSGS is 
important, particularly when renal biopsy is problematic and/or contra-indicated. Thus 
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biomarkers would be a valuable minimally invasive tool for assessing kidney disease as well 
as for clinical monitoring of response to antiretroviral therapy in HIVAN.  
 
Conclusion 
This study demonstrated statistically significant difference between bFGF levels in children 
with HIVAN and HIV positive and negative controls, although it failed to distinguish 
between HIVAN and idiopathic FSGS. Our results in part propose that bFGF is associated 
with renal injury and that continual use of HAART  may slow progression to ESRD. 
However, further studies with a larger sample size are required to assess bFGF as a potential 
predictive tool and its prognostic role in HIVAN development.  
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